Sitemap
All pages
News categories
Latest news
- IACTA Pharmaceuticals and Pharmaleads to Develop the World’s First Epithelial Protective Drug Harnessing Entodogenous Analgesia for the Topical Treatment of Acute and Chronic Ocular Pain
- IACTA Pharmaceuticals et Pharmaleads s’allient dans le développement du premier médicament, exploitant le système antalgique entodogène, pour le traitement topique des todouleurs oculaires aiguës et chroniques
- Promotion of a new management team at Pharmaleads to accelerate the development of its pain relief drug candidates
- Nouvelle équipe de direction chez Pharmaleads pour accélérer le développement de ses candidats médicament dans le traitement de la todouleur
- PHARMALEADS PRESENTS ONE POSTER AT THE INTERNATIONAL HEADACHE CONFERENCE – IHC, DUBLIN, SEPTEMBER 5-8th, 2019
- PHARMALEADS PRESENTS ONE POSTER AND A LECTURE AT THE 50th INTERNANTIONAL NARCOTICS RESEARCH CONFERENCE (INRC), NEW-YORK, JULY 7-11th, 2019
- Two scientific posters presented by Pharmaleads in two prestigious International congresses rewarded in 2018
- PHARMALEADS PRESENTS TWO POSTERS AT THE 17th WORLD CONGRESS ON PAIN – IASP, BOSTON, SEPTEMBER 12-16th, 2018
- Pharmaleads Presents New Data Showing DENKIs, a New Class of Painkillers, to be Devoid of Abuse Potential and Opiate Side-Effects
- DENKI (Dual ENKephalinase Inhibitors), a new class of painkillers devoid of abuse potential and of opiate side-effects
- Pharmaleads to present at BioTrinity 2018 in Lontodon
- Pharmaleads to Present at Biotech Showcase 2018 in San Francisco
- Meeting of Pharmaleads Clinical Advisory Board Confirms Clinical Development Plans for PL265 and PL37
- Pharmaleads CEO to Present at Bio-Europe 2017
- Pharmaleads Reports Positive Ocular Pain Results with PL265, a Novel Dual Enkephalinase Inhibitor (DENKI), at the ARVO 2017 Annual Meeting
- Pharmaleads to Present PL265 for Ocular Pain Results at the ARVO 2017 Annual Meeting in Baltimore
- Pharmaleads announces the opening of french sites in its international Phase IIa clinical study of PL37
- Dr. Pierre-André Wicker joins Pharmaleads’ Board of Directors
- Pharmaleads announces the inclusion of the first patient in Phase IIa study of oral PL37 for pain in diabetic neuropathy
- Pharmaleads and Debiopharm sign licence agreement
